Fig. 1
Antitumour activity. Response rates (a) and durability of response (b) with pembrolizumab in mucosal and nonmucosal melanoma
Fig. 1 | British Journal of Cancer
Antitumour activity. Response rates (a) and durability of response (b) with pembrolizumab in mucosal and nonmucosal melanoma
